Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 3/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | FRK | P42685 | 1/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.68 |
| ▸ | BRAF | P15056 | 14/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5257540 | 1.00 | CSNK1D (1.00) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL25220251 | 0.86 | CSNK1D (0.75) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL5258392 | 0.85 | MAPK13 (0.74) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL5463467 | 0.84 | MAPK13 (0.73) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL5447782 | 0.84 | MAPK13 (0.72) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL5450262 | 0.84 | MAPK13 (0.72) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL3271314 | 0.84 | BRAF (0.74) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL5258671 | 0.83 | MAPK13 (0.71) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL5449791 | 0.83 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 | |
| SCHEMBL9933667 | 0.82 | CSNK1D (0.69) | CSNK1DCSNK1EMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019005-B2 | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2006-03-28 | — | — | US | claimed |
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | claimed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | claimed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | claimed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | claimed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-7019005-B2 | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2006-03-28 | — | — | US | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-6579873-B2 | Treatment of inflammation, arthritis, bone disorders, respiratory system disorders | PHARMACIA CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | disclosed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | CSNK1D 496/4885CSNK1E 677/4885MAPK13 28/4885 |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | CSNK1D 496/4885CSNK1E 677/4885MAPK13 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.